Can-Fite BioPharma Ltd.(CANF) Intrinsic Value & DCF Analysis (2026)
Current Price
$3.06
Last updated: Jun 23, 2026
Price vs Intrinsic Value
Fundamental Score
Weighted across 6 signals
Narrative Score
No change vs previous
Trend Score
Trend data unavailable
The intrinsic value of Can-Fite BioPharma Ltd. (CANF) is estimated at $-2.26 per share based on a 10-year discounted cash flow (DCF) analysis. At the current price of $3.06, the stock appears overvalued relative to its projected cash flow fundamentals. This estimate assumes a -15.77% long-term growth rate and a 10.00% discount rate (calculated: 7.74%), reflecting expected future free cash flow and cost of capital.
The intrinsic value of Can-Fite BioPharma Ltd. (CANF) is estimated at $-2.26 per share based on a 10-year discounted cash flow (DCF) analysis. At the current price of $3.06, the stock appears overvalued relative to its projected cash flow fundamentals. This estimate assumes a -15.77% long-term growth rate and a 10.00% discount rate (calculated: 7.74%), reflecting expected future free cash flow and cost of capital.Valuation Details
Fundamental Details
Narrative Details
Trend Details
Investment Coach
- Price moving to at least a mid-teens discount to fair value
- Improvement in ROIC versus WACC spread
- Meaningful positive shifts in the narrative score direction
Free Cash Flow (in millions)
How Intrinziq Estimates Fair Value
Intrinziq estimates Can-Fite BioPharma Ltd.'s intrinsic value using a discounted cash flow (DCF) model based on free cash flow trends and a market-based discount rate. The model projects future cash flows over ten years and discounts them using a market return assumption to estimate fair value.
Can-Fite BioPharma Ltd.Healthcare
Can-Fite BioPharma Ltd., an Israeli clinical-stage biopharmaceutical company, specializes in the creation of small molecule therapeutic products. These treatments target a range of conditions including various cancers, inflammatory liver disorders, and erectile dysfunction. Its primary drug candidate, Piclidenoson, has successfully advanced through Phase III clinical trials for psoriasis and completed Phase II trials for COVID-19. Another promising asset, Namodenoson, is currently undergoing Phase III clinical evaluation for hepatocellular carcinoma (a form of liver cancer) and is in a Phase IIb study for non-alcoholic steatohepatitis (NASH). Furthermore, CF602 is in preclinical development, aimed at addressing erectile dysfunction. Beyond its drug pipeline, Can-Fite also commercializes a predictive biomarker blood test kit for A3AR. Strategic partnerships are also key to its operations; a licensing and collaboration agreement with CMS Medical covers the development, manufacturing, and commercialization of both Piclidenoson and Namodenoson. Additionally, the company collaborates with Univo Pharmaceuticals to identify and co-develop cannabis-derived formulations intended for various therapeutic applications, including cancer, inflammatory, autoimmune, and metabolic conditions. Originally incorporated in 1994 as Can-Fite Technologies Ltd., the company adopted its current name, Can-Fite BioPharma Ltd., in January 2001 and is headquartered in Petah Tikva, Israel.